Search results
There's A Reason You Have Chin Hair And It's Not Because You're Old
Women's Health via AOL· 3 days agoHormones, PCOS, and hirsutism may cause chin hair in women. Doctors share potential causes and how...
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
Zacks· 4 days agoFree Report) , a clinical-stage company focused on developing novel therapeutics for metabolic and ...
ADVERTISING: Advertorial — Beyond TSH: Other helpful thyroid tests
Coeur d'Alene Press· 4 days agoThyroid disorders are one of the many diseases on the upswing. There are an estimated 20 million...
Selective venous sampling for secondary hypertension - Hypertension Research
Nature· 4 days agoThese authors contributed equally to this work.
Med tech company May Health raises $25M round to treat infertility caused by PCOS - Bizwomen
The Business Journals· 4 days agoClinical-stage medical device company May Health has closed a $25 million Series B financing round...
PCOS infertility treatment developer May Health raises $25M
FierceBiotech· 2 days agoThe startup May Health has gathered $25 million in funding to help continue clinical studies of its...
ACLU Montana: Stop health department, DOJ from harm to transgender people
Daily Montanan via Yahoo News· 2 hours agoPeople who are transgender need to be able to amend their birth certificates and driver’s licenses...
HC Wainwright Analysts Cut Earnings Estimates for Spruce Biosciences, Inc. (NASDAQ:SPRB)
ETF DAILY NEWS· 19 hours agoSpruce Biosciences, Inc. (NASDAQ:SPRB – Free Report) – Equities researchers at HC Wainwright cut their Q2 2024 EPS estimates for Spruce Biosciences in a research note issued to investors on ...
Can Water Pills Help You De-Bloat? Doctors Explain.
Men's Health via Yahoo News· 1 day agoGreene says. Liver cirrhosis, lymphedema (tissue swelling that often occurs in the arms and legs), and hormonal disorders, such as hyperaldosteronism,...
Neurocrine shares new CAH treatment data at endocrinology congress By Investing.com
Investing.com· 4 days agoThe company presented baseline characteristics from the CAHtalyst™ Phase 3 trials of crinecerfont in...